

1 **The application of an extracellular vesicle-based biosensor in early diagnosis and**
2 **prediction of chemoresponsiveness in ovarian cancer**

3
4 **Meshach Asare-Werehene**^{1,2}, Rob Hunter^{4,5}, Emma Gerber^{1,2}, Arkadiy Reunov³, Isaiah Brine⁴,
5 Chia-Yu Chang^{6,7,8}, Chia-Ching Chang^{6,7,8}, Dar-Bin Shieh^{9,10}, Dylan Burger², *Hanan
6 Anis⁵ and *Benjamin K. Tsang^{1,2}

7
8 ¹Departments of Obstetrics & Gynecology and Cellular & Molecular Medicine, Centre for Infection, Immunity and
9 Inflammation, Interdisciplinary School of Health Sciences, University of Ottawa, Ottawa, ON K1N 6N5, Canada

10 ²Chronic Disease Program, Ottawa Hospital Research Institute, The Ottawa Hospital, Ottawa, ON K1Y 4E9, Canada

11 ³St. Francis Xavier University, Department of Biology, 2320 Notre Dame Avenue, Antigonish, NS, B2G 2W5,
12 Canada

13 ⁴Ottawa-Carleton Institute for Biomedical Engineering, University of Ottawa, Ottawa, Ontario, K1N 6N5, Canada

14 ⁵School of Electrical Engineering and Computer Science, University of Ottawa, Ottawa, Ontario, K1N 6N5, Canada

15 ⁶Department of Biological Science and Technology, National Yang Ming Chiao Tung University, Hsinchu, Taiwan
16 30068

17 ⁷Center for Intelligent Drug Systems and Smart Bio-devices (IDS²B), National Yang Ming Chiao Tung University,
18 Hsinchu, Taiwan, 30068

19 ⁸Department of Electrophysics, National Yang Ming Chiao Tung University, Hsinchu, Taiwan, 30010

20 ⁹ Institute of Physics, Academia Sinica, Taipei, Taiwan 10529

21 ¹⁰Institute of Basic Medical Science, Institute of Oral Medicine and Department of Stomatology, National Cheng
22 Kung University Hospital, National Cheng Kung University, Tainan 704, Taiwan.

23 ¹¹Advanced Optoelectronic Technology Center and Center for Micro/Nano Science and Technology, National
24 Cheng Kung University, Tainan 701, Taiwan

25

26 **Running Title: Extracellular vesicle-mediated CDDP secretion in OVCA chemoresistance**

27 *Correspondance:

28 Dr. Benjamin K Tsang, Chronic Disease Program, Ottawa Hospital Research Institute, The
29 Ottawa Hospital (General Campus), Ottawa, Canada K1H 8L6; Tel: 1-613-798-5555 ext
30 72926; Email: btsang@ohri.ca

31

32 Dr. Hanan Anis, School of Electrical Engineering and Computer Science, University of Ottawa,
33 Ottawa, Ontario, K1N 6N5, Canada; Tel: Email: hanis@uottawa.ca

34

35

36 **Author Contributions:** M.A.W., B.K.T., R.H. and H.A. conceived and designed the study.
37 M.A.W. performed all cellular and molecular biology experiments unless otherwise stated. R.H,
38 I.B. and H.A designed biosensor and performed SERS analyses. M.A.W, E.G. and D.B.
39 performed NTA analyses. A.R. performed electron microscopy analyses. D.S. performed energy
40 dispersive X-ray spectroscopy and inductively coupled plasma reactive ion etching. C.Y.C and
41 C.C.C. designed and provided human recombiant pGSN. Patient-derived EV isolation and
42 Western blot was done by E.G. M.A.W. analysed the data and wrote the paper with scientific
43 input and feedback from all authors.

44

45

46 **Competing Interests:** The authors declared no conflicts of interest.

47

48 **ABSTRACT**

49 Ovarian cancer (OVCA) is the most fatal gynecological cancer with late diagnosis and
50 chemoresistance being the main obstacles of treatment success. Since there is no reliable
51 approach to diagnosing patients at an early stage as well as predicting chemoresponsiveness,
52 there is the urgent need to develop a diagnostic platform for such purposes. Extracellular vesicles
53 (EVs) present as an attractive biomarker given their potential specificity and sensitivity to tumor
54 sites. We have developed a novel sensor which utilizes cysteine functionalized gold
55 nanoparticles to simultaneously bind to cisplatin (CDDP) and EVs affording us the advantage of
56 predicting OVCA chemoresponsiveness, histologic subtypes, and early diagnosis using surface
57 enhanced Raman spectroscopy. EVs were isolated and characterized from chemosensitive and
58 resistant OVCA cells lines as well as pre-operative patient blood samples. The mechanistic role
59 of plasma gelsolin (pGSN) in EV-mediated CDDP secretion in OVCA chemoresistance was
60 investigated using standard cellular and molecular techniques. We determined that
61 chemoresistant cells secrete significantly higher levels of small EVs (sEVs) and EVs containing
62 CDDP (sEV-CDDP) compared with their sensitive counterparts. pGSN interacted with cortactin
63 (CTTN) and both markers were significantly upregulated in chemoresistant patients' tumors
64 compared with the sensitive patients. Silencing pGSN decreased EV and EV-CDDP secretions in
65 the resistant cells whereas its over-expression in sensitive cells upregulated EV and EV-CDDP
66 secretion, suggesting the potential role of pGSN in EV-mediated CDDP export. sEV/CA125

67 ratio outperformed CA125 and sEV individually in predicting early stage, chemoresistance,
68 residual disease, tumor recurrence, and patient survival. These findings highlight pGSN as a
69 potential therapeutic target as well as providing a potential diagnostic platform to detect OVCA
70 earlier and predict chemoresistance; an intervention that will positively impact patients' survival.

71 **INTRODUCTION**

72 Ovarian cancer (OVCA) remains the most fatal gynecological cancer with a 5-year survival rate
73 of 45% primarily due to late diagnosis and chemoresistance (1-3). Although patients initially
74 respond to treatment (primary surgical debulking and chemotherapy), about 50 – 70% of the
75 patients relapse and become resistant to further treatment (3). The 5-year survival rate for stage 1
76 patients is >90% whereas that for stage 2, 3 and 4 are ~70%, ~39%, and ~17% respectively (1,
77 3). However, only about 19% of ovarian cancer patients are diagnosed at the early stage despite
78 the use of conventional biomarkers such as CA125, HE4, ROMA, and OVA1 (1-6). This
79 suggests the urgent need for highly reliable and effective diagnostic platforms for early stage
80 disease and chemoresistant prediction.

81 Plasma gelsolin (pGSN; also known as secreted GSN) is a multi-functional actin binding protein
82 and the secreted isoform of the GSN gene (7-9). pGSN is implicated in the progression,
83 chemoresistance, and metastasis of a plethora of cancer types including OVCA (10-18). We have
84 previously demonstrated that pGSN is highly expressed in chemoresistant OVCA tumors and also
85 transported via small extracellular vesicles (sEVs) (10, 15, 16). sEV-pGSN autoregulates its own
86 gene expression and confers resistance to chemosensitive cells in a paracrine manner through the
87 activation of the FAK/AKT/HIF1a pathway (10). Additionally, sEV-pGSN induces caspase-3
88 dependent apoptosis as well as suppresses the anti-tumor functions of immune cells such as

89 CD8+ T cells, CD4+ T cells, and M1 macrophages (15, 16). Although pGSN is closely
90 associated with sEV secretion, we have yet to determine the role of pGSN in sEV secretion.

91 EVs present as an attractive biomarker given they carry bioprints of the secreting cells and could
92 capture the molecular landscape of cancer cells. This offers a superior advantage for cancer
93 diagnostic tests compared with other biomarkers. EVs are secreted from most cells and are also
94 present in liquid biopsies such as urine, plasma, and ascites. EVs are broadly categorized into
95 apoptotic bodies (>1000 nm), large EVs (200 – 500 nm) and small EVs (30 – 300 nm) and serve
96 as carriers for transporting molecular signatures such as proteins, RNA, DNA, and miRNAs (19,
97 20). The contents of the cargo could induce phenotypic and genetic changes in the recipient cells.
98 sEVs play a key role in tumorigenesis and chemoresistance in different cancer types (15, 21-23).
99 Chemoresistant OVCA cells secrete increased levels of sEVs containing pGSN which confers
100 chemoresistance on otherwise chemosensitive cells as well as downregulate the tumor-killing
101 functions of immune cells in the tumor microenvironment (10, 15, 16). Despite the potential
102 diagnostic utility of sEVs, detecting EV specific antigens using conventional techniques like
103 polymerase chain reaction (PCR) and enzyme-linked immunosorbent assay (ELISA) present as a
104 major obstacle in cancer diagnostics. Thus, the use of technologies that could effectively detect
105 the biochemical fingerprints of EVs will significantly enhance their clinical utility as opposed to
106 targeting specific markers.

107 Surface enhanced Raman spectroscopy (SERS) has the capacity to examine the biochemical
108 structure of biological analytes and presents as a useful tool in differentiating cancer cells from
109 normal cells (24, 25). Interestingly, the application of SERS in liquid biopsy analyses has
110 encountered major setbacks due to the heterogeneity of samples and interferences from large
111 proteins. Similar obstacles are likely to be encountered in chemoresistance prediction given that

112 not all circulating EVs originate from cancer cells, and those share biochemical characteristics
113 with the target EVs. We have recently developed a novel sensor which utilizes cysteine
114 functionalized gold nanoparticles to simultaneously bind to cisplatin (CDDP) and EVs affording
115 us the advantage of quantifying EVs and EV-CDDP with high accuracy using SERS (26). This
116 unique biosensor will enable us to overcome the challenges of tumor heterogeneity and protein
117 interferences.

118 In this study, we investigated the application of an EV-based novel biosensor in the diagnosis of
119 early-stage OVCA and the prediction of chemoresistance. Additionally, we examined the
120 regulation of EV-mediated CDDP efflux by pGSN in chemoresistant OVCA cells. We found that
121 pGSN is a key regulator of EV secretion and EV-mediated release of CDDP from chemoresistant
122 OVCA cells. sEV/CA125 is also a strong indicator for stage 1 OVCA as well as predictor of
123 chemoresistance.

124

125 **MATERIALS AND METHODS**

126 **Ethics Statement**

127 All the subjects recruited provided a written informed consent and the study was conducted in
128 accordance with the appropriate guidelines approved by the Centre hospitalier de l'Université de
129 Montreal (CHUM) Ethics Committee (IRB approval number; BD 04-002) and the Ottawa Health
130 Science Network Research Ethics Board (IRB approval number; OHSN-REB 20150646-01H).

131

132 **Plasma Samples:**

133 Ninety-nine (99) ovarian cancer patients (high grade serous, HGS; 69, low grade serous, LGS; 4,
134 not verified; 26) with predetermined CA125 levels and twenty (20) healthy non-cancerous
135 subjects provided plasma samples for extracellular vesicle (EV) isolation, characterization, and
136 analyses. Patients were recruited at the CHUM from 1992 – 2012 and did not receive any
137 neoadjuvant chemotherapy or radiotherapy. All patients were managed with primary surgery.
138 Gynecologic-oncologic pathologists examined all samples and assigned tumor grade and
139 histologic subtypes in accordance with the International Federation of Gynecology and
140 Obstetrics (FIGO) criteria. Computed Tomography imaging and CA125 levels during follow-ups
141 were used to define disease-free survival (DFS; time of diagnosis to time of recurrence) and
142 overall survival (OS; time of diagnosis to time of death). Details of patient demographics and
143 clinical outcomes are outlined in **Supplementary Table S1**.

144

145 **Interrogation of OVCA public datasets**

146 Ovarian cancer public datasets were interrogated using <http://www.rocplot.org/ovarian/index> and
147 <http://gepia.cancer-pku.cn/index.html> on 06/16/2022. The differential expressions (box plot;
148 chemoresistance vs. chemosensitive) and test performances (ROC curves; chemoresistance
149 prediction) of GSN, CTTN, ABCB1, MRP2, and RAB27A (n=958; sensitive=862; resistant=96;
150 platinum) were investigated. Spearman's correlation tests were performed to assess the
151 association between pGSN and the other genes. Significant correlations were inferred as $P \leq$
152 0.05.

153

154 **Reagents.**

155 Cis-diaminedichloroplatinum (CDDP), phenylmethylsulfonyl fluoride (PMSF), aprotinin,
156 dimethyl sulfoxide (DMSO), sodium orthovanadate (Na₃VO₄), CCK-8, and Hoechst 33258 were
157 supplied by Millipore Sigma (St. Louis, MO). Two preparations of pGSN siRNA (siRNA1 and
158 2) and scrambled sequence siRNA (control) were purchased from Integrated DNA Technology
159 (Iowa, USA) and Dharmacon (Colorado, USA), respectively. Human recombinant plasma
160 gelsolin (hrpGSN) were synthesized and provided by Dr. Chia-Ching Chang, National Yang
161 Ming Chiao Tung University, Taiwan. pGSN cDNA and 3.1A vector plasmids were provided by
162 Dr. Dar-Bin Shieh, National Cheng Kung University Hospital, Taiwan. pCT-CD63-GFP was
163 purchased from System Biosciences, LLC. See **Supplementary Table S2** for details on
164 antibodies and other reagents.

165

166 **Ovarian Cancer Cell Lines.**

167 Chemosensitive and chemoresistant OVCA cell lines (1.6×10^6 cells) of high grade serous
168 (HGS; TOV3041G, TOV3133 and OV90) and endometrioid (A2780s and A2780cp) histologic
169 subtypes were used for all *in vitro* studies. Dr. Anne-Marie Mes-Masson (CHUM, Montreal,
170 Canada) generously donated the HGS cell lines whereas the endometrioid cell lines were
171 generously donated by Dr. Barbara Vanderhyden (Ottawa Hospital Research Institute, Ottawa,
172 Canada). Quality control was performed to prevent any batch-to-batch changes on the
173 morphology and growth rate. In addition, cell lines were regularly authenticated and tested for
174 *Mycoplasma* contamination using Plasmotest™ Mycoplasma Detection kit (InvivoGen; catalog
175 number: rep-pt1). The HGS OVCA cells were maintained in OSE medium (Wisent Inc. St-Bruno,
176 QC, Canada) supplemented with 10% FBS (Millipore Sigma; St. Louis, MO, USA), 250 µg/mL
177 amphotericin B, and 50 mg/mL gentamicin (Wisent Inc. St-Bruno, QC, Canada). The

178 endometrioid OVCA cells were maintained in Gibco RPMI 1640 (Life Technologies, Grand
179 Island, NY, USA) supplemented with 10% FBS (Millipore Sigma; St. Louis, MO), 50 U/mL
180 penicillin, 50 U/mL streptomycin, and 2 mmol/L l-glutamine (Gibco Life Technologies, NY,
181 USA). All experiments were carried out in serum-free media. Details on the mutations of the cell
182 lines used are described in **Supplementary Table S3**.

183

184 **pGSN Gene Interference.**

185 Chemoresistant cells were transfected with siRNA (50 nM, 24 h; scramble as controls) and
186 sensitive cells transfected with cDNA (2 µg; 24 h; empty vectors as controls) using
187 lipofectamine 2000, and were subsequently treated with CDDP (10 µM; 24 h)) then harvested for
188 analysis as previously described (27-29). Two different siRNAs were used for each target to
189 exclude off-target effects. Western blot was used to confirm pGSN knock-down and over-
190 expression (30). See **Supplementary Table S2** for details on antibodies and **Supplementary**
191 **Table S4** for customized siRNA oligonucleotide duplexes.

192

193 **Extracellular Vesicle (EVs) Isolation and Characterization.**

194 EVs were isolated and characterized from serum-free conditioned media from cultured cells as
195 well as ovarian cancer patient plasma as described (31). Differential ultracentrifugation was used
196 to isolate EVs from conditioned media while ExoQuick Ultra was used for the plasma samples.
197 Conditioned media were centrifuged at 300 ×g (10 mins at RT) to remove cells and debris,
198 20,000 ×g (20 mins at RT) to remove large EVs (microparticles), and then at 100,000 ×g (90
199 mins at 4°C) to pellet sEVs. For plasma-derived EV isolation, 100 µL of ExoQuick precipitation
200 reagent is added to plasma (40 µL in 500 µL of 0.1µm filtered PBS) and incubated on ice for 30

201 mins. The content is then centrifuged at $3,000 \times g$ for 10 mins and the suspension discarded. The
202 pellet is then re-suspended in a buffer (provided by the manufacturer), transferred into pre-
203 washed ExoQuick Ultra columns, and then centrifuged at $1,000 \times g$ for 30 secs. The receiving
204 tube is then detached and EVs collected. EVs are then characterized using nanoparticle tracking
205 analyses (particle size distribution and concentration), Western blot (EV-specific markers) and
206 transmission electron microscopy (EV size and purity). Isolated EVs that were not used
207 immediately were suspended in PBS and stored at -80°C for subsequent analyses.

208

209 **Nanoparticle Tracking Analysis (NTA).**

210 EVs diluted in PBS were analyzed, using the ZetaView PMX110 Multiple Parameter Particle
211 Tracking Analyzer (Particle Metrix, Meerbusch, Germany) in size mode, and ZetaView software
212 version 8.02.28, as previously described (31, 32). With 11 camera positions, EVs were captured
213 at 21°C .

214

215 **sEV-GFP tagging and uptake.**

216 Chemosensitive and chemoresistant OVCA cell lines (1.6×10^6 cells) were transfected with
217 exosome cyto-tracer, pCT-CD63-GFP (SBI System Biosciences; CYTO120-PA-1; $1 \mu\text{g}$) in
218 serum-free RPMI-1640 and then treated with CDDP ($10 \mu\text{M}$; 24 h). Cells were fixed and
219 processed for confocal microscopy. Details on antibodies are described in **Supplementary Table**
220 **S2.**

221

222 **Protein Extraction and Western blot Analysis.**

223 Western blotting (WB) procedure for proteins were carried out as described previously (27, 28,
224 30). After protein transfer, membranes were incubated with primary antibodies (1:1000) in 5%
225 (wt/vol) blotto and subsequently with the appropriate horseradish peroxidase (HRP)-conjugated
226 secondary antibody (1:2000) in 5% (wt/vol) blotto. See **Supplementary Table S2** for details of
227 antibodies used. Chemiluminescent Kit (Amersham Biosciences) was used to visualize the
228 peroxidase activity. Signal intensities generated on the film were measured densitometrically
229 using Image J.

230

231 **Assessment of Cell Proliferation and Apoptosis.**

232 Apoptosis and cell proliferation were assessed morphologically with Hoechst 33258 nuclear
233 stain and colorimetrically with the CCK-8 assay, respectively. “Blinded” counting approach was
234 used to prevent experimental bias with the Hoechst 33258 nuclear staining.

235

236 **Transmission Electron Microscopy (TEM).**

237 OVCA cell were pelleted (4000 ×g; 20 min) and processed, as previously described (33). Resin
238 sections were stained with uranyl acetate and lead citrate solutions and examined with a Jeol
239 JEM 1230 transmission electron microscope (Akishima, Japan).

240

241 **Immunoelectron Microscopy (iEM).**

242 Cell pellets (4000 g; 20 min) were processed as previously described (33). The grids were
243 washed three times in PBST, immunostained with anti-pGSN **antibody (Supplementary Table**
244 **S2)**, rinsed in distilled water, stained with uranyl acetate and lead citrate, and photographed with
245 a Jeol JEM 1230 transmission electron microscope (Akishima, Japan).

246 **EDS and ICP-MS**

247 Energy Dispersive Spectroscopy (EDS) was performed in High-Resolution Transmission
248 Electron Microscopy (HR-TEM, JEM-2010/JEOL Co. 200 KV) in NCKU for the quantitative
249 analysis of elemental compositions and distributions in chemoresistant cells, particularly
250 platinum signal that represent the anti-cancer drug. The samples were dispersed in ethanol and
251 dropped onto a copper grid with an amorphous carbon film followed by evaporation of the
252 solvent in a vacuum desiccator. The elemental composition was detected and quantified by EDS.
253 In order to determine the Cisplatin content in the sEVs and in the condition medium, the Pt ion
254 present in the drug was analyzed by THERMO Element XR High-resolution ICP-mass
255 spectrometer (Element XR, Thermo Fisher Scientific, Bremen, Germany). Conditioned media
256 were collected and sEVs were isolated using differential ultra-centrifugation before analysis. The
257 sEVs pellets were lysed with lysis buffer (1% Triton X-100, 0,1 M Tris-HCl pH 7.4, 0.1% SDS)
258 containing protease inhibitors (Sigma-Aldrich). Then, the sEVs lysates were digested by adding
259 200 μ L or 50 μ L of concentrated nitric acid (Optima Grade, Fisher Scientific, Cambridge, MA)
260 and kept at at 60°C for 2 hours. The final digested solutions were diluted with deionized water
261 (DI Water). Indium (1 μ g/L) was added to the specimens as internal standard. The same matrix
262 (lysing solution, nitric acid) was used as the calibration standard for the external control. Cell
263 culture medium samples were diluted 1:100 with DI Water before performing the Pt analysis,
264 adding only Indium as internal standard to minimize the effect of instrumental variation. The
265 levels of the drug into the medium were expressed as ng of Cisplatin per mL of the solution.

266

267 **SERS quantification of sEV and CDDP**

268 Cysteine capped gold nanoparticles were synthesized using the citrate reduction method to form
269 particles from Au³⁺. After the particles had formed, they were washed via centrifugation and re-
270 suspended in 10 mM NaOH with 1 μM cysteine. The amino acid preferentially bound to the gold
271 surfaces due to the formation of a gold-thiol bond. To analyse sEV samples, they were first
272 sonicated for 15 minutes to break-up the vesicles before mixing with the nanoparticles and
273 incubating overnight. Before Raman measurement NaCl was added to the sEV-nanoparticle
274 mixture to initiate aggregation, and this process was measured by means of an in-house built
275 Raman spectrometer (785 nm excitation, 30 mW, 0.65 NA objective, Kaiser f/18i spectrograph,
276 TE cooled Andor CCD). CDDP concentration could be inferred based on the aggregation rate of
277 the particles, with increasing drug concentration resulting in faster aggregation (26). The steady-
278 state SERS spectrum contained the signature of the sEV components which had also bound to
279 the nanoparticles, and this spectrum could be used to quantify the sEVs in the sample using
280 multi-variate regression (26).

281

282 **Statistical Analyses.**

283 The SPSS software version 25 (SPSS Inc., Chicago, IL, USA) and Graphpad Prism 7 (San
284 Diego, CA, USA) were used to perform all statistical analyses and two-sided $P \leq 0.05$ considered
285 to indicate statistical significance. Receiving operating characteristic (ROC) curves were used to
286 assess the performances of sEV/CA125, sEV and CA125 over their entire range of values. The
287 area under the curve (AUC) was used as an index of global test performance. The association
288 between sEVs and CA125 was analysed using Pearson's correlation test (two-tailed). The means
289 of sEVs and sEV/CA125 levels were plotted against stage, residual disease, histological
290 subtypes, tumor recurrence, chemoresistance and survival using scatter plots and statistical

291 analyses performed by using unpaired *t*-test; Gaussian distribution was tested. The relationship
292 of these dichotomous variables to other clinicopathologic correlates was examined using Fisher
293 exact test, T test and Kruskal Wallis Test as appropriate. Survival curves (DFS and OS) were
294 plotted with Kaplan Meier and P-values calculated using the log-rank test. Univariate and
295 multivariate Cox proportional hazard models were used to assess the hazard ratio (HR) for
296 CA125, pGSN, stage (FIGO), residual disease and age as well as corresponding 95% confidence
297 intervals (CIs).

298

299 **RESULTS**

300 **Extracellular vesicle isolation and characterizations from OVCA cell lines**

301 To investigate the role of pGSN in EV-mediated secretion of CDDP in OVCA chemoresistance,
302 OVCA cell lines of HGS and Endometrioid subtypes were cultured with and without CDDP
303 treatment (10 μ M; 24 h) and their conditioned media were collected for EV isolation and
304 characterization. Conditioned media was filtered with 0.22 μ m pore size filter and EVs isolated
305 using differential ultra-centrifugation (Fig. 1A). EVs were characterized using nanoparticle
306 tracking analyses to determine particle size distribution and concentration (Fig. 1B), immune-
307 gold electron microscopy to determine particle size, EV purity and gelsolin content (Fig. 1C).
308 Based on the particle isolation and characterizations, the EVs had an average size of 130 nm and
309 were positive for CD63 and CD9 markers suggesting they are sEVs. Electron microscopy
310 confirmed that they contained secreted gelsolin (Fig. 1). SEVs from the plasma of OVCA
311 patients and non-OVCA subjects were isolated using ExoQuick ULTRA (System Biosciences),
312 which employs the use of a polymer for robust vesicle precipitation, low speed centrifugation,

313 and column filtration (Fig. 1D). SEVs were characterized using nanoparticle tracking analysis
314 and Western blotting (Fig. 1E). Unlike the sEV-free plasma, the sEVs isolated from patients'
315 plasma had an average median size of 136 nm and were positive for sEV markers (CD 9, CD63,
316 and CD81) but negative for GM130, suggesting they are mainly sEVs (Fig. 1E and F). The
317 presence of GAPDH also suggests the sEVs were intact (Fig. 1F).

318 **Chemoresistant OVCA cells secrete higher sEV-CDDP and exhibit a lateral EV secretion** 319 **pattern**

320 Chemosensitive (A2780s) and chemoresistant (A2780cp) cells were treated with or without
321 CDDP (10 μ M; 24 h) in a serum-free conditioned media (Fig. 2). The conditioned media was
322 collected and sEVs isolated. CDDP concentrations were determined in the sEVs as well as EV-
323 free conditioned media using inductively coupled plasma reactive ion etching (ICP) (Fig. 2A).
324 We observed that sEVs derived from chemoresistant cells contain significantly higher levels of
325 CDDP compared with that of chemosensitive cells (Fig. 2 A). Meanwhile, there were no
326 significant differences in the CDDP concentration detected in the serum-free conditioned media
327 of both cells (Fig. 2A). The OVCA cells collected were processed for transmission and immune-
328 gold electron microscopy (Fig. 2B-C). We observed a lateral or peripheral secretion of EVs in
329 more than 50% of the chemoresistant cells when treated with CDDP; a phenomenon that was not
330 seen in chemosensitive cells as well as non-treated chemoresistant cells (Fig. 2B). Colloidal gold
331 granules labeling pGSN were also present in EVs (Fig. 2B). Interestingly, the conventional EV
332 secretion via multivesicular bodies and exocytosis were seen in chemoresistant cells not treated
333 with CDDP as well as the chemosensitive cells (Fig. 2C). We also assessed the platinum
334 distribution in the chemoresistant cells after CDDP treatment using energy dispersive x-ray
335 spectroscopy (EDS) (Fig. 2D). Cellular distribution of platinum was not significantly different

336 between chemoresistant cells treated with CDDP and those not treated (Fig. 2D), suggesting that
337 CDDP might have been exported via sEV secretion.

338 **pGSN and CTTN are highly expressed in human chemoresistant OVCA tumors and their**
339 **protein contents in cell lines do not reduce upon CDDP treatment**

340 sEV-mediated secretion of CDDP is a key determinant of OVCA chemoresistance; however, the
341 underlying mechanism is not known. Given pGSN has been shown to be a marker of
342 chemoresistance in OVCA as well as play a major role in EV biology; we investigated its
343 potential role in sEV-mediated OVCA chemoresistance. We interrogated string-db.org and found
344 that while there was no interaction between pGSN and drug transport proteins (p-glycoprotein;
345 ABCB1 and ABCC2) as well as RAB27A, there was a potential interaction between pGSN and
346 CTTN (Fig. 3A). We further interrogated the ovarian cancer TCGA public dataset
347 (<http://gepia.cancer-pku.cn/index.html>) on 06/16/2022 to assess the correlation (Spearman
348 coefficient) between pGSN and CTTN, RAB27A, or ABCB1. We found that pGSN positively
349 correlated with CTTN and both proteins were significantly elevated in chemoresistant tumors
350 compared with chemosensitive tumors (Fig. 3B and Supp. Fig. S1). A positive correlation was
351 found between pGSN and MRP2, p-gp, and RAB27A (Supp. Fig. S1B-C). Additionally, we
352 interrogated OV datasets (<http://www.rocplot.org/ovarian/index>) on 06/16/2022 to determine the
353 differential expression (box plot; chemoresistance vs. chemosensitive) and test performance
354 (receiver operating characteristic (ROC) analysis; chemoresistance prediction) of GSN, CTTN,
355 ABCB1, MRP2, and RAB27A (Fig. 3B and Supp. Fig. S1) (n=958; sensitive=862; resistant=96).
356 All patients had serous tumors, had received platin-based treatment, and response was based on
357 progression free survival at 6 months. Using ROC analysis, we examined the test performance of
358 pGSN (area under the curve (AUC)=0.56; p=0.03) and CTTN (AUC: 0.6; p<0.0001) and found

359 both markers are significantly predictive of OVCA chemoresistance (Fig. 3C). We observed that
360 P-glycoprotein but not MRP2 nor RAB27A are significantly predictive of chemoresistance in
361 human OVCA tumors (Supp. Fig. S1A).

362 To begin investigating the role of sEV-mediated chemoresistance in OVCA, chemosensitive
363 (A2780s, TOV3041G, TOV3133) and chemoresistant (A2780cp and OV90) OVCA cells were
364 treated with or without CDDP (10 μ M; 24 h) (Fig. 3D). pGSN, CTTN, P-gp, RAB27A and
365 GAPDH contents were assessed by Western blot. Cisplatin-induced cell death was analyzed by
366 Hoechst staining, and cell viability was verified by CCK-8 assay (Fig. 3D). pGSN and CTTN
367 contents were reduced by CDDP in the chemosensitive cells but not in the chemoresistant cells
368 (Fig. 3D). These results were independent of histologic subtype. Notably, pGSN content was
369 higher in chemoresistant compared to chemosensitive cells (Fig. 3D). P-glycoprotein and
370 RAB27A contents were not detectable in the sensitive cells; however, weak signals were
371 observed in the chemoresistant cells (Fig. 3D). Also, CDDP-induced apoptosis was significantly
372 higher in the chemosensitive cells compared with the chemoresistant cells (Fig. 3D).

373 **pGSN regulates sEV release of CDDP and chemoresponsiveness in OVCA cells**

374 The role of pGSN in sEV-mediated release of CDDP was further investigated in OVCA cells.
375 Gold nanoparticles (AuNP) were synthesized and capped with cysteine (Au-cys) as previously
376 demonstrated and characterized. Due to the strong negative charge of Au-cys particles, they form
377 a mono-stable colloid in the absence of sEVs containing CDDP (Fig. 4A and B). Upon the
378 addition of sEV containing CDDP, the cysteine residues are attacked by CDDP resulting in the
379 reduction of the surface charges of the Au-NP (Fig. 4A and B). This results in Au-NP-sEV-
380 CDDP aggregation which could be measured by Surface Enhance Raman Spectroscopy (SERS);

381 a response that is proportional to the concentration of sEV and CDDP. Mono-stable colloid
382 formation and aggregations of the particles were confirmed using transmission electron
383 microscopy (Fig. 4B).

384 pGSN was silenced in chemoresistant cells using siRNAs (50 nM; 24 h; empty vector as a
385 control) (Fig. 4C) and overexpressed in chemosensitive cells using cDNA (2 µg; 24 h) and
386 human recombinant pGSN (hrpGSN, 10 µM; 24 h) (Fig. 4D and Supp. Fig. S2A). pGSN, CTTN
387 and GAPDH contents were assessed by Western blot and CDDP-induced death analyzed by
388 Hoechst staining. sEVs were isolated and their levels together with sEV-CDDP concentrations
389 determined using SERS. pGSN knock-down resulted in the downregulation of CTTN content; a
390 phenomenon that decreased sEV secretion as well as sEV-CDDP content (Fig. 4C and Supp. Fig.
391 S2B). Additionally, pGSN knock-down sensitized the chemoresistant cells to CDDP-induced
392 apoptosis (Fig. 4C). pGSN overexpression in chemosensitive cells increased CTTN content, sEV
393 secretion as well as sEV-CDDP content (Fig. 4D and Supp. Fig. S2C). pGSN overexpression
394 also suppressed CDDP-induced apoptosis in the chemosensitive cells (Fig. 4D). Additionally, we
395 observed that hrpGSN promoted sEV secretion in chemosensitive cells; an observation which
396 was consistent with pGSN overexpression by cDNA (Fig. 4D).

397 The above findings potentially suggest that pGSN regulates CTTN expression, which leads to
398 enhanced secretion of sEVs in chemoresistant OVCA cells. Also, pGSN is enriched with sulphur
399 and metallic binding sites; properties that might facilitate its direct binding to platinum, leading
400 to enhanced CDDP packaging in sEVs and eventual release from the cell (Fig. 4E).

401 **SEV to CA125 ratio (sEV/CA125) is a strong predictor of stage 1 disease,**
402 **chemoresponsiveness and favorable survival outcomes in OVCA patients**

403 After characterizing our biosensor in OVCA cell lines, we extended its application to measuring
404 SEV concentration in human patient plasma. Plasma samples were collected from 99 OVCA
405 patients with HGS, LGS and unverified histologic subtypes (**Supplementary Table S2**). Plasma-
406 derived sEVs from OVCA patients and non-OVCA subjects were isolated and characterized
407 (Fig. 1). The biosensor application was tested with the buffers used in the sEV isolation to ensure
408 they do not interfere with the SERS measurement (Supp. Fig. S3A and B). Although the buffers
409 increased the aggregation of the nanogold particles, this could easily be normalized and did not
410 affect CDDP quantification (Supp. Fig. 3B and C). Mono-stable colloid formation and Au-NP
411 aggregation with the plasma-derived sEV were confirmed using transmission electron
412 microscopy before SERS quantification was performed (Fig. 5A).

413 The sEV concentration and EV/CA125 ratio were determined and their mean \pm SD values
414 correlated with patient clinical outcomes (stage, tumor recurrence, survival, chemoresistance,
415 and residual disease) (Figs. 5, 6 and Supp. Fig. S4). We observed that patients with advanced
416 stages of OVCA had levels of sEVs comparable to those in early stages (Fig. 5B); however, no
417 significant difference in sEV concentrations was observed among the patients and the control
418 healthy individuals. There's also no correlation detected with the presence of residual disease
419 (RD<1cm vs, RD>1cm), chemoresistance (PFI<6mo vs. PFI>6mo), tumor recurrence (yes vs.
420 no), and the level of CA125 (low vs. high) (Supp. Fig. S4A). SEVs had a negative correlation
421 with CA125, hence we developed a ratio with both markers to investigate their clinical utility
422 (Supp. Fig. S4B). SEV/CA125 ratio had better clinical utility compared to sEV and CA125
423 concentrations alone with regards to OVCA stage, tumor recurrence and disease state (Fig. 5C).
424 However, a trend (although not significant) was observed with residual disease and histologic
425 differentiation subtypes (Supp. Fig. S4C). Using ROC analysis, we determined the test

426 performances of sEV, sEV/CA125, and CA125 in predicting patient clinical outcomes (Fig. 5D).
427 We found that sEV/CA125 was the most robust in predicting stage 1 disease, non-recurrence,
428 patient survival, chemoresponsiveness and optimal residual disease in OVCA patients (Fig. 5D).
429 Kaplan-Meier survival curves with dichotomized sEV/CA125 ratio (low vs. high, cut-off = 68.8)
430 and log rank test were used to compare the survival distributions between the groups (Fig. 6A).
431 We observed that patients with high sEV/CA125 had significantly improved disease free survival
432 (DFS; 63 months vs. 18 months, $p=0.018$) as well as overall survival (OS; 83 months vs. 48
433 months, $p=0.037$) compared with patients with low sEV/CA125 (Fig. 6A). We further
434 investigated if sEV/CA125 could be used to predict multiple clinical outcomes using a heat map
435 (Fig. 6B-C). Compared with sEV and CA125 individually, sEV/CA125 ratio provided a
436 significant prediction value for multiple clinical outcomes. Patients with increased sEV/CA125
437 were mostly in stage 1 and did not develop recurrence or resistance to treatment (Fig. 6B and C).
438 SEV and CA125 concentrations alone were not predictive of clinical outcomes.

439

440 **DISCUSSION**

441 For the first time, we have shown evidence that pGSN plays a regulatory role in sEV secretion as
442 well as sEV-mediated release of CDDP; factors that are involved in OVCA chemoresistance.
443 Additionally, we extended the application of our novel sEV-based biosensor to a small OVCA
444 patient cohort to develop a highly sensitive diagnostic platform for the detection of early stage
445 OVCA and prediction of chemoresponsiveness.

446 Drug efflux is a key determinant of chemoresistance in a lot cancer types, including OVCA
447 cancer (34-37). Most studies have identified multi-drug resistant proteins such as p-glycoprotein

448 to be responsible for drug efflux in cancer cells, thus rendering chemotherapeutic agents unable
449 to induce death in cancer cells (36, 37). In this present study, we have demonstrated that sEVs
450 serve as a vehicle for exporting chemotherapeutic agents from OVCA cancer cells rather than
451 using drug transport channels. Chemoresistant OVCA cells treated with CDDP secreted
452 increased amount of sEVs as well as sEV containing CDDP compared with their sensitive
453 counterparts. This could potentially explain why targeting drug transport channels such as P-
454 glycoprotein has not yielded any therapeutic benefit in OVCA given the sEVs role in drug efflux.
455 This suggests that sEV secretion is a potential therapeutic target to tackle chemoresistance in
456 OVCA.

457 Targeting sEV secretion also demands understating the mechanism underlying why
458 chemoresistant cells secrete more sEVs and sEV-CDDP. pGSN is overexpressed in
459 chemoresistant OVCA compared with chemosensitive cells and transported via sEVs (10). The
460 positive association between pGSN and sEVs made us investigate the role of pGSN in sEV
461 secretion. We observed that silencing pGSN reduced the expression of CTTN (involved in sEV
462 release mechanisms) in chemoresistant cells resulting in decreased sEV secretion and EV-CDDP
463 release. The opposite happened when pGSN was overexpressed in chemosensitive OVCA cells.
464 Targeting pGSN in the chemoresistant cells resulted in increased accumulation of CDDP leading
465 to increased apoptosis, suggesting that pGSN is a key regulator of CTTN expression. These
466 findings are consistent with the study in which pGSN and CTTN were found to be upregulated
467 and co-localized in resistant pancreatic cancer cell lines. Furthermore, recent studies have shown
468 that proteins rich in sulphur and amines have high affinity for cisplatin binding. Since pGSN has
469 these properties as well as more than 10 metal binding sites, there is a possibility that it could

470 directly bind to CDDP and facilitate their packaging into sEVs for secretion. This will be worth
471 investigating in the future.

472 Late diagnosis is a huge challenge to therapeutic success and patient survival. Developing a
473 highly sensitive diagnostic platform for early OVCA diagnosis is of urgent need. With
474 heterogeneity and protein interference as major challenges when using SERS for sEV analysis,
475 we have developed a biosensor to overcome this challenge. This biosensor is able to react with
476 sEVs and CDDP simultaneously; a strategy that enables us to quantitate both sEVs and CDDP
477 simultaneously using SERS. This strategy is highly sensitive and superior to other studies that
478 have developed gold nanoparticles for sEV analysis alone.

479 We examined the diagnostic utility of our sEV-based biosensor in a small pre-operative OVCA
480 cohort. Although sEVs could be detected and quantified, their diagnostic value was not as strong
481 as when combined with CA125. This could potentially be due to the fact that the biosensor
482 recognized sEVs from origins other than OVCA. To overcome this, we used a ratio of sEVs to
483 CA125. We observed that the sEV/CA125 ratio had a significantly improved diagnostic value.
484 sEV/CA125 was significantly elevated in stage 1 patients compared to stages 2-4 and
485 outperformed CA125 and sEV in identifying stage 1 disease. This is a promising marker given
486 conventional biomarkers have only provided modest diagnostic value. Interestingly, sEV/CA125
487 also outperformed CA125 and sEVs in predicting tumor recurrence, chemoresistance, residual
488 disease and patient survival. This is exciting given there is no reliable biomarker to predict tumor
489 recurrence and chemoresistance. OVCA patients with increased sEV/CA125 had prolonged
490 survival compared with those with low sEV/CA125, suggesting that sEV/CA125 could be used
491 as a potential marker for early stage OVCA and predict patient survival outcomes prior treatment
492 or surgery. With limited biomarker options for early stage OVCA and prediction of

493 chemoresistance, sEV/CA125 could be further investigated to provide the needed diagnostic
494 tool.

495

496 **CONCLUSION**

497 We have demonstrated that pGSN regulates sEV and sEV-CDDP secretions via CTTN
498 upregulation leading to decreased intracellular CDDP accumulation and apoptosis. These
499 processes further suppress chemo-responsiveness in OVCA cells. Additionally, we have applied
500 a novel biosensor to develop a platform that is effective in identifying stage 1 disease and
501 predicting tumor recurrence and chemoresistance. Although these findings are promising and
502 have an important clinical relevance, further validation of the platform is needed in a larger
503 patient cohort and animal models.

504 **REFERENCES**

- 505 1. Release notice - Canadian Cancer Statistics 2019. Health Promot Chronic Dis Prev Can.
506 2019;39(8-9):255.
- 507 2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA: a cancer journal for clinicians.
508 2018;68(1):7-30.
- 509 3. Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer
510 statistics, 2018. CA: a cancer journal for clinicians. 2018;68(4):284-96.
- 511 4. Gu P, Pan LL, Wu SQ, Sun L, Huang G. CA 125, PET alone, PET-CT, CT and MRI in diagnosing
512 recurrent ovarian carcinoma: a systematic review and meta-analysis. Eur J Radiol. 2009;71(1):164-74.
- 513 5. Romagnolo C, Leon AE, Fabricio ASC, Taborelli M, Polesel J, Del Pup L, et al. HE4, CA125 and risk
514 of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic
515 mass: An Italian multicenter study. Gynecologic oncology. 2016;141(2):303-11.
- 516 6. Nowak M, Janas L, Stachowiak G, Stetkiewicz T, Wilczynski JR. Current clinical application of
517 serum biomarkers to detect ovarian cancer. Przegląd menopauzalny = Menopause review.
518 2015;14(4):254-9.
- 519 7. Kwiatkowski DJ, Stossel TP, Orkin SH, Mole JE, Colten HR, Yin HL. Plasma and cytoplasmic
520 gelsolins are encoded by a single gene and contain a duplicated actin-binding domain. Nature.
521 1986;323(6087):455-8.
- 522 8. Yin HL, Kwiatkowski DJ, Mole JE, Cole FS. Structure and biosynthesis of cytoplasmic and secreted
523 variants of gelsolin. The Journal of biological chemistry. 1984;259(8):5271-6.

- 524 9. Feldt J, Schicht M, Garreis F, Welss J, Schneider UW, Paulsen F. Structure, regulation and related
525 diseases of the actin-binding protein gelsolin. *Expert reviews in molecular medicine*. 2019;20:e7.
- 526 10. Asare-Werehene M, Nakka K, Reunov A, Chiu CT, Lee WT, Abedini MR, et al. The exosome-
527 mediated autocrine and paracrine actions of plasma gelsolin in ovarian cancer chemoresistance.
528 *Oncogene*. 2020;39(7):1600-16.
- 529 11. Ma X, Sun W, Shen J, Hua Y, Yin F, Sun M, et al. Gelsolin promotes cell growth and invasion
530 through the upregulation of p-AKT and p-P38 pathway in osteosarcoma. *Tumour biology : the journal of*
531 *the International Society for Oncodevelopmental Biology and Medicine*. 2016;37(6):7165-74.
- 532 12. Wang PW, Abedini MR, Yang LX, Ding AA, Figeys D, Chang JY, et al. Gelsolin regulates cisplatin
533 sensitivity in human head-and-neck cancer. *International journal of cancer Journal international du*
534 *cancer*. 2014;135(12):2760-9.
- 535 13. Tsai MH, Wu CC, Peng PH, Liang Y, Hsiao YC, Chien KY, et al. Identification of secretory gelsolin
536 as a plasma biomarker associated with distant organ metastasis of colorectal cancer. *Journal of*
537 *molecular medicine (Berlin, Germany)*. 2012;90(2):187-200.
- 538 14. Xu Y, Zhang Y, Wang L, Zhao R, Qiao Y, Han D, et al. miR-200a targets Gelsolin: A novel
539 mechanism regulating secretion of microvesicles in hepatocellular carcinoma cells. *Oncology reports*.
540 2017;37(5):2711-9.
- 541 15. Asare-Werehene M, Tsuyoshi H, Zhang H, Salehi R, Chang CY, Carmona E, et al. Plasma Gelsolin
542 Confers Chemoresistance in Ovarian Cancer by Resetting the Relative Abundance and Function of
543 Macrophage Subtypes. *Cancers*. 2022;14(4).
- 544 16. Asare-Werehene M, Communal L, Carmona E, Han Y, Song YS, Burger D, et al. Plasma Gelsolin
545 Inhibits CD8(+) T-cell Function and Regulates Glutathione Production to Confer Chemoresistance in
546 Ovarian Cancer. *Cancer research*. 2020;80(18):3959-71.
- 547 17. Chen CC, Chiou SH, Yang CL, Chow KC, Lin TY, Chang HW, et al. Secreted gelsolin desensitizes
548 and induces apoptosis of infiltrated lymphocytes in prostate cancer. *Oncotarget*. 2017;8(44):77152-67.
- 549 18. Giampazolias E, Schulz O, Lim KHJ, Rogers NC, Chakravarty P, Srinivasan N, et al. Secreted
550 gelsolin inhibits DNGR-1-dependent cross-presentation and cancer immunity. *Cell*. 2021;184(15):4016-
551 31.e22.
- 552 19. Whitham M, Parker BL, Friedrichsen M, Hingst JR, Hjorth M, Hughes WE, et al. Extracellular
553 Vesicles Provide a Means for Tissue Crosstalk during Exercise. *Cell metabolism*. 2018;27(1):237-51.e4.
- 554 20. Budnik V, Ruiz-Canada C, Wendler F. Extracellular vesicles round off communication in the
555 nervous system. *Nature reviews Neuroscience*. 2016;17(3):160-72.
- 556 21. Chen G, Huang AC, Zhang W, Zhang G, Wu M, Xu W, et al. Exosomal PD-L1 contributes to
557 immunosuppression and is associated with anti-PD-1 response. *Nature*. 2018;560(7718):382-6.
- 558 22. Wang Q, Lu Q. Plasma membrane-derived extracellular microvesicles mediate non-canonical
559 intercellular NOTCH signaling. *Nature communications*. 2017;8(1):709.
- 560 23. Marimpietri D, Airoldi I, Faini AC, Malavasi F, Morandi F. The Role of Extracellular Vesicles in the
561 Progression of Human Neuroblastoma. *International journal of molecular sciences*. 2021;22(8).
- 562 24. Jermyn M, Mercier J, Aubertin K, Desroches J, Urmev K, Karamchandiani J, et al. Highly Accurate
563 Detection of Cancer In Situ with Intraoperative, Label-Free, Multimodal Optical Spectroscopy. *Cancer*
564 *research*. 2017;77(14):3942-50.
- 565 25. Paidi SK, Rizwan A, Zheng C, Cheng M, Glunde K, Barman I. Label-Free Raman Spectroscopy
566 Detects Stromal Adaptations in Premetastatic Lungs Primed by Breast Cancer. *Cancer research*.
567 2017;77(2):247-56.
- 568 26. Robert A. Hunter MA-W, Aseel Mandour, Benjamin K. Tsang and Hanan Anis. Determination of
569 Chemoresistance in Ovarian Cancer by Simultaneous Quantification of Exosomes and Exosomal Cisplatin
570 with Surface Enhanced Raman Scattering. *Sensors and Actuators: B Chemical*. 2022;354(131237).

- 571 27. Abedini MR, Qiu Q, Yan X, Tsang BK. Possible role of FLICE-like inhibitory protein (FLIP) in
572 chemoresistant ovarian cancer cells in vitro. *Oncogene*. 2004;23(42):6997-7004.
- 573 28. Abedini MR, Muller EJ, Bergeron R, Gray DA, Tsang BK. Akt promotes chemoresistance in human
574 ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like
575 inhibitory protein. *Oncogene*. 2010;29(1):11-25.
- 576 29. Ali AY, Abedini MR, Tsang BK. The oncogenic phosphatase PPM1D confers cisplatin resistance in
577 ovarian carcinoma cells by attenuating checkpoint kinase 1 and p53 activation. *Oncogene*.
578 2012;31(17):2175-86.
- 579 30. Abedini MR, Wang PW, Huang YF, Cao M, Chou CY, Shieh DB, et al. Cell fate regulation by
580 gelsolin in human gynecologic cancers. *Proceedings of the National Academy of Sciences of the United
581 States of America*. 2014;111(40):14442-7.
- 582 31. Burger D, Vinas JL, Akbari S, Dehak H, Knoll W, Gutsol A, et al. Human endothelial colony-
583 forming cells protect against acute kidney injury: role of exosomes. *The American journal of pathology*.
584 2015;185(8):2309-23.
- 585 32. Vinas JL, Burger D, Zimpelmann J, Haneef R, Knoll W, Campbell P, et al. Transfer of microRNA-
586 486-5p from human endothelial colony forming cell-derived exosomes reduces ischemic kidney injury.
587 *Kidney international*. 2016;90(6):1238-50.
- 588 33. Reunov A, Pimenova E, Reunova Y, Menchinskaiya E, Lapshina L, Aminin D. The study of the
589 calpain and caspase-1 expression in ultrastructural dynamics of Ehrlich ascites carcinoma necrosis. *Gene*.
590 2018;658:1-9.
- 591 34. Mo L, Pospichalova V, Huang Z, Murphy SK, Payne S, Wang F, et al. Ascites Increases
592 Expression/Function of Multidrug Resistance Proteins in Ovarian Cancer Cells. *PLoS One*.
593 2015;10(7):e0131579.
- 594 35. Ishikawa T, Ali-Osman F. Glutathione-associated cis-diamminedichloroplatinum(II) metabolism
595 and ATP-dependent efflux from leukemia cells. Molecular characterization of glutathione-platinum
596 complex and its biological significance. *The Journal of biological chemistry*. 1993;268(27):20116-25.
- 597 36. Morrow CS, Peklak-Scott C, Bishwokarma B, Kute TE, Smitherman PK, Townsend AJ. Multidrug
598 resistance protein 1 (MRP1, ABCC1) mediates resistance to mitoxantrone via glutathione-dependent
599 drug efflux. *Molecular pharmacology*. 2006;69(4):1499-505.
- 600 37. Tiwari AK, Sodani K, Dai CL, Ashby CR, Jr., Chen ZS. Revisiting the ABCs of multidrug resistance in
601 cancer chemotherapy. *Current pharmaceutical biotechnology*. 2011;12(4):570-94.

602

603


604

605

606

607

608 FIGURE LEGENDS




609

610 **Figure 1: Extracellular vesicle (EVs) isolation and characterization.** (A) Conditioned media
 611 from cultured OVCA cells were collected and filtered using 0.22 µm filter. Differential ultra-
 612 centrifugation was used to isolate small EVs after which they were characterized using (B)
 613 nanoparticle tracking analyses (NTA; particle size distribution and concentration) and (C)
 614 electron microscopy (EM). (D) Small EVs were isolated from the plasma of human OVCA

615 patients (n=99) and non-OVCA subjects (n=20) using Exoquick Ultra technique. EVs were then
 616 characterized using (E) nanoparticle tracking device (size distribution) and (F) Western blot
 617 analyses (small EV markers; CD9, CD63, CD81, negative marker; GM130, vesicle integrity
 618 marker; GAPDH).

619



620

621

622

623 **Figure 2: Chemoresistance OVCA cells secrete higher sEV-CDDP and exhibit abnormal**
624 **EV secretion pattern.** (A) sEV-CDDP content is higher in chemoresistant cells compared with
625 chemosensitive cells. Chemosensitive (A2780s) and chemoresistant (A2780cp) were cultured
626 and treated with or without CDDP (10 μ M; 24 h). Conditioned media were collected and sEVs
627 isolated using differential ultra-centrifugation. CDDP content in the sEVs and conditioned media
628 was analyzed using inductively coupled plasma reactive ion etching (ICP). (B and C)
629 Chemoresistance OVCA cells when treated with CDDP exhibits peripheral secretion of sEVs
630 which is not found in untreated chemoresistant cells. Chemoresistance OVCA cells were treated
631 with or without CDDP (10 μ M; 24 h). Cells were processed and sEV secretion analyzed using
632 transmission and immuno-gold electron microscopy (As0; A2780s without treatment, As10;
633 A2780s treated with 10 μ M CDDP, Cp0; A2780cp without treatment and Cp10; A2780cp treated
634 with 10 μ M CDDP. (D) Platinum (Pt), calcium (Ca), nitrogen (N) and Sulphur (S) distribution
635 within chemoresistant cells were analyzed using energy dispersive x-ray spectroscopy (EDS).

636

637

638


639

640

641

642

643



644

645 **Figure 3: pGSN and CTTN are highly expressed in chemoresistant OVCA patient tumors**
 646 **and their protein contents in cell lines do not reduce upon CDDP treatment.** (A) Using
 647 string-db.org, we found a strong interaction between pGSN and CTTN but not ABCB1 (p-gp),
 648 ABCC2, RAB27A. (B – C) Our investigation of TCGA public dataset revealed that pGSN
 649 positively correlates with CTTN expression and both proteins are highly elevated in
 650 chemoresistant OVCA patients (n=958). The test performances of pGSN and CTTN were

651 evaluated using ROC curves and significant predictions were observed. (D) Chemosensitive
652 (A2780s, TOV3041G, TOV3133) and chemoresistant (A2780cp and OV90) cells were treated
653 with or without CDDP (10 μ M; 24 h). pGSN, CTTN, P-gp, RAB27A and GAPDH contents were
654 assessed by Western blot. Cisplatin-induced cell death was analysed by Hoechst staining and
655 CCK-8 assay. Results are expressed as means \pm SD from three independent replicate
656 experiments. [D, (a; **P<0.01 vs b, a; ***P<0.001 vs c)].

657

658

659

660

661

662

663

664

665


666

667

668

669

670
671
672
673
674
675
676
677
678
679
680
681
682



683 **Figure 4: pGSN regulates sEV release of CDDP and chemoresponsiveness.** pGSN
684 downregulation in chemoresistant cells reduced CTTN content, sEV production and sEV-CDDP
685 release whereas the vice-versa occurs when pGSN is over-expressed in chemosensitive cells. (A)
686 Negatively charged cysteine capped gold particles (AuNP) react with CDDP and sEVs to form
687 aggregates which is used for the SERS quantification. The rate of aggregation is proportional to
688 the concentrations of CDDP and sEV. (B). Transmission electron microscope (TEM) images of

689 mono-stable colloid of AuNP (without sEVs; left panel) and aggregated cysteine capped AuNP
690 (with sEVs and CDDP; right panel). The biological components in the solution did not appear
691 visible in the TEM images. pGSN was (C) silenced in chemoresistant cells (siRNA; 50 nM, 24 h)
692 and (D) over-expressed in chemosensitive cells (cDNA; 2 ug, rhpGSN; 10 uM; 24 h). Cells were
693 then treated with or without CDDP (10 uM; 24 h). pGSN, CTTN and GAPDH contents were
694 assessed by Western blot and cisplatin-induced cell death analysed by Hoechst staining. sEV and
695 CDDP concentrations were determined by biosensor aggregation using Raman spectroscopy. (E)
696 A hypothetical model suggesting the role of pGSN in the sEV release of CDDP from
697 chemoresistant OVCA cells. Results are expressed as means \pm SD from three independent
698 replicate experiments. [A - C, (a; **P<0.01 vs b)].

699

700

701


702

703

704

705

706



707

708 **Figure 5: sEVCA125 predicts stage 1 and tumor recurrence with high test accuracy. (A)**

709 Transmission electron microscope (TEM) images of mono-stable colloid of AuNP (without

710 plasma-derived sEVs; left panel) and aggregated cysteine capped AuNP (with plasma-derived

711 sEVs; right panel). The biological components in the solution did not appear visible in the TEM

712 images. SEVs were isolated from the plasma of human OVCA patient with pre-determined

713 CA125, sEV or sEV/CA125 were correlated with patient clinical outcomes. (B) The mean levels
714 of sEV concentrations were compared between early (I + II) and late (III + IV) stages as well as
715 stage I and >stage 1 groups. Patients with late stage OVCA had lower levels of sEV
716 concentration compared with early stage or stage 1 patients. (C) The mean levels of sEV/CA125
717 were correlated with OVCA clinical outcomes (stages, tumor recurrence and survival). (D) The
718 test performances of sEV, sEV/CA125 and CA125 in the prediction of stage 1, tumor recurrence,
719 survival, chemoresistance and residual disease were compared using ROC curves.

720

721

722

723

724


725

726

727

728

729



730

731 **Figure 6: High levels of sEV/CA125 provide favorable survival outcomes to OVCA**
 732 **patients.** sEV/CA125 levels in OVCA patients (N=99) were correlated with progression-free
 733 survival (PFS) and overall survival (OS). Kaplan-Meier survival curves with dichotomized
 734 sEV/CA125 levels (low and high groups, cut-off = 68.8) and log rank test were used to compare
 735 the survival distributions between the groups. N = number of patients (B) sEV/CA125 predicts
 736 more than one clinical outcome of OVCA. SEV/CA125, sEV and CA125 were used in a heat
 737 map analyses to predict stage 1 and tumor recurrence as well as stage 1 and chemoresistance.

